Boston Scientific Corp (BSX)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 2,282,000 | 2,202,000 | 2,143,000 | 2,149,000 | 1,985,000 | 1,876,000 | 1,511,000 | 1,430,000 | 1,142,000 | 866,000 | 1,104,000 | 908,000 | 1,077,000 | 1,205,000 | 495,000 | 165,000 | -138,000 | -392,000 | -74,000 | 252,000 |
| Revenue (ttm) | US$ in thousands | 16,746,000 | 15,910,000 | 15,228,000 | 14,707,000 | 14,240,000 | 13,757,000 | 13,400,000 | 13,045,000 | 12,682,000 | 12,567,000 | 12,329,000 | 12,162,000 | 11,888,000 | 11,469,000 | 11,196,000 | 10,122,000 | 9,913,000 | 10,110,000 | 10,158,000 | 10,786,000 |
| Pretax margin | 13.63% | 13.84% | 14.07% | 14.61% | 13.94% | 13.64% | 11.28% | 10.96% | 9.00% | 6.89% | 8.95% | 7.47% | 9.06% | 10.51% | 4.42% | 1.63% | -1.39% | -3.88% | -0.73% | 2.34% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $2,282,000K ÷ $16,746,000K
= 13.63%
The pretax margin of Boston Scientific Corp has shown fluctuating trends over the past few years, with some periods of negative margins indicating challenges in generating profits before accounting for taxes. Despite these fluctuations, there has been a general upward trajectory in the pretax margin starting from negative levels in mid-2020 to reaching double-digit percentages by the end of 2023 and into 2024. This upward trend signifies improvements in the company's ability to control costs, increase operating efficiency, or drive revenue growth.
In the most recent period, the pretax margin for December 31, 2024, stood at 13.63%, demonstrating a healthy level of profitability before tax expenses. The consecutive quarters of double-digit pretax margins reflect the company's success in efficiently managing expenses and increasing earnings relative to its revenue. This positive trend suggests that Boston Scientific Corp is effectively leveraging its resources to enhance profitability and create value for its stakeholders.
Overall, the trending improvement in the pretax margin indicates that Boston Scientific Corp has been making strides in enhancing its operational performance and financial health, positioning the company on a positive trajectory for continued growth and financial success.
Peer comparison
Dec 31, 2024